Daniele Zink,
Principal Research Scientist and Team Leader, Institute of Bioengineering and Nanotechology,
Agency for Science Technology and Research (A*STAR)
Daniele Zink earned her PhD from the University of Heidelberg, Germany in 1995, and was appointed in 1996 as Research Assistant Professor at the Ludwig-Maximilians University (LMU), Munich, Germany. In 2001 she completed her Habilitation in Cell Biology and was awarded funding of a Junior Group from the Volkswagen-Foundation. She was head of the Junior Group at the LMU until she was appointed in 2007 as Team Leader and Principal Research Scientist by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research in Singapore. Her research focuses on stem cells and predictive methods for in vitro toxicology/nanotoxicology. This work has been awarded by the US Society of Toxicology and Zink has won the prestigious LUSH Prize (2016, Science Category). Zink is co-founder of the spin-off Cellbae that is specialized on stem cell products and applications, holds 12 patents/patent applications, is Editorial Board Member of Scientific Reports and has > 70 publications, which include publications in Nature, Nature Reviews Cancer, Archives of Toxicology and Nanotoxicology.
Stem Cell-Based Screening Platforms for the Efficient and Accurate Prediction of Nephrotoxicity in Humans
Tuesday, 11 July 2017 at 09:30
Add to Calendar ▼2017-07-11 09:30:002017-07-11 10:30:00Europe/LondonStem Cell-Based Screening Platforms for the Efficient and Accurate Prediction of Nephrotoxicity in HumansStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
The presentation will summarize our work on stem cell-based screening platforms for the prediction of nephrotoxicity, and in particular renal proximal tubular toxicity, in humans. Our most advanced technology is based induced pluripotent stem cells (iPSC), which are differentiated by the currently most rapid and efficient protocol into renal proximal tubular-like cells ( Kandasamy et al., 2015). In combination with one of our recently established in vitro methods for nephrotoxicity prediction (Li et al., 2013; 2014) and machine learning (Su et al., 2014), an iPSC-based platform has been developed that predicts proximal tubular cell toxicity in humans with 87% test balanced accuracy (Kandasamy et al., 2015). Our iPSC-based technologies are compatible with our high-throughput platform for nephrotoxicity prediction (Su et al., 2015), and we are currently exploring predictive kidney-on-a-chip approaches.
Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-07-11 09:30:002017-07-11 10:30:00Europe/LondonStem Cell-Based Screening Platforms for the Efficient and Accurate Prediction of Nephrotoxicity in HumansStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
